IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a synthetic analogue of endogenous IGF-1, engineered with an extended half-life and enhanced receptor binding profile that has made it a focal point in preclinical research involving anabolic signaling, muscle cell biology, and metabolic regulation. Structurally, IGF-1 LR3 differs from native IGF-1 by the substitution of arginine for glutamic acid at position 3 and the addition of a 13-amino-acid N-terminal extension, modifications that reduce its affinity for IGF-binding proteins (IGFBPs) and substantially prolong systemic activity. These properties have led researchers to investigate IGF-1 LR3 as a tool for studying growth factor signaling cascades with greater temporal resolution than is possible with native IGF-1.
Preclinical interest in IGF-1 LR3 has grown considerably in recent years, particularly in fields intersecting sports science, metabolic disease modeling, and cellular proliferation research. Studies have examined how this modified peptide interacts with the IGF-1 receptor (IGF-1R), downstream PI3K/AKT/mTOR pathways, and cross-talk with insulin signaling — making it a versatile probe for understanding growth hormone axis biology in laboratory settings.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.
IGF-1 LR3 1MG — Research-Grade Reference Material IGF-1 LR3 1MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Kisspeptin - 10MG
$45.00$33.75 with 1st order
CJC 1295 No DAC (5MG) Ipamorelin (5MG) - 10MG
$75.00$56.25 with 1st order
CJC1295 w/ DAC - 5MG
$55.00$41.25 with 1st order
TB-500 - 5MG
$45.00$33.75 with 1st order
Frequently Asked Questions
What is IGF-1 LR3 and how does it differ from regular IGF-1?
IGF-1 LR3 is a synthetic analogue of insulin-like growth factor-1 that incorporates two key structural modifications: an arginine-for-glutamic-acid substitution at position 3 and a 13-amino-acid N-terminal extension. These changes reduce binding to IGF-binding proteins (IGFBPs), resulting in a markedly longer half-life — estimated at 20–30 hours in preclinical models compared to minutes for native IGF-1 — and enhanced availability at the IGF-1 receptor.
What receptor does IGF-1 LR3 bind to in research models?
Research indicates that IGF-1 LR3 primarily binds the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor that, upon activation, initiates intracellular signaling through the PI3K/AKT/mTOR and RAS/MAPK/ERK pathways. Studies have also noted partial binding affinity for the insulin receptor, though this is substantially lower than its affinity for IGF-1R.
What has research shown about IGF-1 LR3 and muscle cell signaling?
In vitro and animal studies have investigated IGF-1 LR3’s ability to stimulate myoblast proliferation and differentiation. Research suggests it activates mTORC1-dependent protein synthesis pathways and may upregulate satellite cell activity, both of which are considered central to skeletal muscle hypertrophy in preclinical models. These findings remain confined to controlled laboratory environments.
How long is the half-life of IGF-1 LR3?
Preclinical research estimates the half-life of IGF-1 LR3 at approximately 20–30 hours, a significant extension over native IGF-1, which has a plasma half-life of only a few minutes when unbound. This prolonged activity is attributed to the reduced affinity for IGF-binding proteins that would otherwise sequester the peptide and limit receptor engagement.
Is IGF-1 LR3 used in human clinical trials?
As of current literature, IGF-1 LR3 research has been primarily conducted in cell culture systems and animal models. It is classified as a research compound for laboratory use only and is not approved for therapeutic application in humans. Researchers should review the current regulatory landscape for peptide compounds in their jurisdiction before initiating any studies.
How does IGF-1 LR3 relate to the GH/IGF-1 axis?
In the growth hormone/IGF-1 axis, growth hormone stimulates hepatic production of endogenous IGF-1, which then mediates many of GH’s anabolic effects at the tissue level. IGF-1 LR3 is a structural analogue designed to replicate and extend this downstream signaling. Researchers studying GH secretagogues like CJC-1295 and ipamorelin often use IGF-1 LR3 as a complementary tool to examine downstream effector mechanisms.
What metabolic pathways has IGF-1 LR3 been studied in?
Research has explored IGF-1 LR3 in the context of glucose uptake, lipid metabolism, and insulin receptor cross-signaling. Studies in animal models have examined its capacity to influence GLUT4 translocation, adipocyte differentiation, and hepatic glucose output — pathways relevant to metabolic disease research. These investigations remain at the preclinical stage.
What formats is IGF-1 LR3 available in for research?
For laboratory research purposes, IGF-1 LR3 is typically supplied in lyophilized powder form, which is reconstituted with bacteriostatic water or sterile saline prior to use in cell culture or animal study protocols. Source Peptides offers IGF-1 LR3 at 1MG for qualified research applications.
Structural Biochemistry of IGF-1 LR3
Understanding why IGF-1 LR3 has become such a widely used research tool requires examining its biochemistry relative to native IGF-1. Endogenous IGF-1 is a 70-amino-acid peptide produced primarily in the liver in response to growth hormone stimulation. In circulation, the vast majority of IGF-1 is bound to one of six IGF-binding proteins — predominantly IGFBP-3 — which regulate its availability, transport, and half-life.
IGF-1 LR3 1MG — Research-Grade Reference Material IGF-1 LR3 1MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Kisspeptin - 10MG
$45.00$33.75 with 1st order
CJC 1295 No DAC (5MG) Ipamorelin (5MG) - 10MG
$75.00$56.25 with 1st order
CJC1295 w/ DAC - 5MG
$55.00$41.25 with 1st order
TB-500 - 5MG
$45.00$33.75 with 1st order
IGF-1 LR3 addresses the limitation of rapid sequestration through two deliberate modifications. The N-terminal 13-amino-acid extension and the Arg3 substitution together reduce binding affinity for IGFBPs by approximately 1,000-fold in some estimates. This means that in research models, a significantly higher proportion of the administered peptide remains free to engage with the IGF-1 receptor, making it a far more potent and longer-acting experimental probe than native IGF-1.
Receptor Binding Dynamics
The IGF-1 receptor (IGF-1R) is a transmembrane tyrosine kinase that belongs to the insulin receptor superfamily. Upon IGF-1 LR3 binding, receptor autophosphorylation triggers two principal downstream cascades: the PI3K/AKT/mTOR pathway, which governs protein synthesis and cell survival, and the RAS/MAPK/ERK pathway, which influences cell proliferation and differentiation. Research has characterized IGF-1 LR3’s binding kinetics to IGF-1R as comparable to or slightly greater than native IGF-1, making it a high-fidelity tool for receptor activation studies without the rapid clearance that limits native IGF-1 utility.
IGF-1 LR3 in Muscle Biology Research
Perhaps the most extensively explored domain in IGF-1 LR3 research involves skeletal muscle biology. Studies have investigated its role in stimulating myoblast proliferation, satellite cell activation, and protein synthesis — three processes central to our understanding of muscle hypertrophy and repair mechanisms in preclinical models.
mTOR Pathway Activation Studies
In vitro research using C2C12 myoblast cell lines has demonstrated that IGF-1 LR3 significantly upregulates phosphorylation of AKT (Ser473) and S6K1, two key nodes in the mTORC1 signaling cascade. mTORC1 activation is considered a master regulator of ribosomal biogenesis and translational efficiency — in other words, the molecular gating mechanism for increased protein synthesis in muscle cells. Researchers have used IGF-1 LR3 to model this signaling environment with greater experimental control due to its extended activity window, which allows for longer observation periods without repeated peptide additions in cell culture systems.
Satellite Cell and Myogenesis Studies
Satellite cells are quiescent myogenic progenitor cells that become activated following muscle damage or growth stimuli. Animal studies have explored whether IGF-1 LR3 administration accelerates satellite cell entry into the cell cycle and subsequent differentiation into myofibers. Research in rodent models has suggested that systemic IGF-1 LR3 exposure is associated with increased satellite cell activation markers, including MyoD and myogenin expression, although the mechanistic interpretation of these findings continues to be refined in the literature.
This area of muscle research intersects with tissue repair peptide studies. As explored in the TB-500 research guide, thymosin beta-4 promotes actin dynamics and cellular migration in healing tissue — a mechanistically distinct but complementary pathway to the growth factor-driven proliferative signaling that IGF-1 LR3 activates.
Metabolic Research Applications
Beyond muscle biology, IGF-1 LR3 has been studied as a probe for metabolic signaling, particularly in the context of insulin sensitivity, glucose homeostasis, and adipose tissue dynamics. The structural overlap between the IGF-1R and insulin receptor families means that IGF-1 LR3 offers a useful research model for examining cross-talk between growth factor and metabolic signaling networks.
Glucose Uptake and GLUT4 Research
Studies in adipocyte and myocyte cell models have examined IGF-1 LR3’s capacity to stimulate GLUT4 translocation to the plasma membrane — the rate-limiting step in insulin-stimulated glucose uptake. Research suggests that IGF-1R activation can drive AKT-mediated phosphorylation of AS160 (TBC1D4), a key GLUT4-regulatory GTPase-activating protein, resulting in increased membrane GLUT4 abundance. These findings have led researchers to explore IGF-1 LR3 as a tool for studying insulin resistance models where the insulin receptor signaling axis may be impaired but IGF-1R pathways remain intact.
Adipogenesis and Fat Cell Differentiation
Animal model research has investigated IGF-1 LR3’s influence on adipocyte differentiation. Some studies suggest that IGF-1R activation can both promote preadipocyte differentiation through PPAR-γ-dependent mechanisms and simultaneously activate lipolytic pathways depending on the cellular context. This metabolic duality makes IGF-1 LR3 an interesting tool for studying the competing anabolic and catabolic pressures in metabolic disease models, though interpretations remain complex and context-dependent.
Researchers studying metabolic peptides alongside IGF-1 LR3 may also be interested in how SLU-PP-322 targets the ERR nuclear receptor family to modulate mitochondrial biogenesis — a parallel approach to studying metabolic enhancement through entirely distinct receptor mechanisms.
IGF-1 LR3 and the GH/IGF-1 Axis: Contextualizing the Research
IGF-1 LR3 research is most meaningfully interpreted within the broader framework of the growth hormone/IGF-1 axis. Growth hormone, secreted from the anterior pituitary, stimulates hepatic IGF-1 production through GH receptor activation of JAK2/STAT5 signaling. The resulting IGF-1 then mediates many of GH’s peripheral effects — including muscle anabolism, bone growth, and metabolic regulation — through the IGF-1R system that IGF-1 LR3 is designed to engage.
Researchers studying GH secretagogue peptides like ipamorelin and CJC-1295 often reference IGF-1 LR3 as a downstream comparator. As detailed in the CJC-1295 + Ipamorelin stack research guide, these peptides work by stimulating endogenous GH release, which subsequently drives IGF-1 production. IGF-1 LR3, by contrast, bypasses this upstream cascade entirely and acts directly at the tissue level — making the two research approaches complementary tools for dissecting which aspects of GH/IGF-1 axis activity depend on pulsatile GH release versus sustained IGF-1R engagement.
CJC-1295 No DAC / Ipamorelin 10MG for research →
Comparison with Native IGF-1 in Research Settings
| Feature | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Half-life | Minutes (free form) | ~20–30 hours |
| IGFBP binding affinity | High | ~1,000× reduced |
| IGF-1R binding | High | Comparable or slightly higher |
| Amino acid length | 70 AA | 83 AA (13 AA extension) |
| Research utility | Short-window signaling studies | Extended-duration signaling studies |
| Endogenous origin | Yes (hepatic) | No (synthetic analogue) |
Cellular Proliferation and Anti-Apoptosis Research
IGF-1 LR3 has been explored as a research tool in cancer biology and cell survival studies, where the PI3K/AKT pathway plays a well-characterized role in regulating apoptosis. Research in various cell line models has examined how sustained IGF-1R activation via IGF-1 LR3 influences Bcl-2 family protein expression, caspase activation, and cell cycle checkpoint progression. These studies are important for understanding both the proliferative biology of growth factor signaling and, critically, the potential safety considerations that researchers must account for when designing experimental protocols.
Some research groups have also investigated IGF-1 LR3 in the context of neuronal survival and neurite outgrowth. Given the PI3K/AKT pathway’s known role in neuroprotection, preclinical studies have explored whether IGF-1R activation can support neuronal cell viability under conditions of oxidative stress — a line of investigation that overlaps with research on neuroprotective peptides like those reviewed in the Pinealon research guide.
Laboratory Handling and Research Protocols
For researchers working with IGF-1 LR3 in laboratory settings, proper handling is essential to maintaining peptide integrity and ensuring experimental reproducibility. IGF-1 LR3 is typically supplied in lyophilized powder form and should be reconstituted with bacteriostatic water or sterile saline (0.9% NaCl) immediately before use. Acetic acid (0.1% solution) is sometimes used as a reconstitution vehicle for improved solubility at lower concentrations.
Storage and Stability Considerations
- Lyophilized IGF-1 LR3 is stable at −20°C for extended periods when protected from repeated freeze-thaw cycles
- Reconstituted solutions should be stored at 4°C and used within a recommended research window, typically 2–4 weeks
- Researchers should avoid exposure to direct light and high temperatures, which can accelerate peptide degradation
- Protein-based additives such as BSA (0.1%) are sometimes included in storage solutions to minimize adsorption to container surfaces
- Cell culture applications commonly use concentrations in the nanomolar range (1–100 nM), though experimental protocols vary
Researchers sourcing growth hormone axis peptides for complementary studies may also consider Ipamorelin 10MG Nasal Spray for research →
Considerations for Research Design
Several methodological considerations are important when incorporating IGF-1 LR3 into research protocols. First, because IGF-1 LR3 engages both IGF-1R and insulin receptor to varying degrees, researchers must account for potential insulin receptor-mediated confounds when interpreting metabolic data. Use of receptor-selective inhibitors (e.g., picropodophyllin for IGF-1R or S961 for insulin receptor) as experimental controls is advisable in mechanistic studies.
Second, the prolonged half-life of IGF-1 LR3 — while experimentally useful — means that washout periods in in vitro studies must be carefully considered. Residual receptor activation can confound time-course experiments if scheduling is not accounted for in the experimental design.
Third, researchers studying IGF-1 LR3 alongside anabolic peptide stacks should be aware that the peptide tier list framework widely used in the research community places IGF-1 LR3 among high-mechanism-depth compounds — those with well-characterized receptor pharmacology but still limited clinical translation, requiring careful experimental design to extract reproducible findings.
IGF-1 LR3 1MG — sourced for laboratory research →
Where These Fit in Your Research Library
Researchers exploring the GH/IGF-1 axis and anabolic signaling pathways may find these related compounds relevant to complementary study designs:
- CJC-1295 No DAC / Ipamorelin 10MG Nasal Spray → — upstream GH secretagogue stack for GH pulse and IGF-1 axis studies
- MOTS-C 10MG Nasal Spray → — mitochondrial-derived peptide for parallel metabolic signaling research
- IGF-1 LR3 1MG → — the primary compound covered in this guide, available for qualified research
Browse the full SourcePeptides research catalog for a complete listing of available research-grade peptide compounds.
Final Takeaway: IGF-1 LR3 as a Research Tool
IGF-1 LR3 occupies a distinctive position in the peptide research landscape as an engineered analogue purpose-built to overcome the primary limitation of endogenous IGF-1 — its rapid clearance by binding proteins. By extending the active half-life and improving receptor bioavailability, IGF-1 LR3 has enabled researchers to conduct more detailed studies of IGF-1R-mediated signaling in skeletal muscle, metabolic tissue, and neuronal cell models than would otherwise be possible with native IGF-1.
Research to date has documented its capacity to activate the mTOR protein synthesis axis, stimulate myoblast proliferation, influence GLUT4-mediated glucose uptake, and modulate cell survival pathways — findings that collectively underscore the peptide’s value as a mechanistic probe for growth factor biology. As with all preclinical research tools, findings from IGF-1 LR3 studies must be interpreted within their experimental context, and the compound remains a research-only compound without approved clinical application. Researchers are encouraged to remain current with peer-reviewed literature and regulatory guidance as this field continues to evolve.
Sources & Further Reading
- Tomas FM et al. — “Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats” — European Journal of Endocrinology (2002)
- Sandhu MS et al. — “Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer” — Journal of the National Cancer Institute (2002)
- Clemmons DR — “Involvement of insulin-like growth factor-I in the control of glucose homeostasis” — Current Opinion in Pharmacology (2006)
- PubMed Search — IGF-1 LR3 Muscle Signaling Studies
- Florini JR et al. — “Actions of IGFs on skeletal muscle function: roles in muscle development” — Molecular Reproduction and Development (1996)
